Here are five quick facts:
1. The stock has a 50-day moving average of $47 and a market cap of $2.39 billion.
2. NuVasive, a medical device company, reported earnings of $0.30 earnings per share last quarter, surpassing analysts’ estimate by $0.09.
3. NuVasive had revenue of $192.40 million last quarter with analysts’ consensus estimate being $189.30 million.
4. Analysts at Goldman Sachs downgraded NuVasive shares by stating it as a “neutral” rating as opposed to its former “buy” rating.
5. Despite Goldaman Sach’s rating, the company still has an average rating of “buy” and an average price of $53.07.
For more device-related news:
8 trends in the North American neurosurgery market
Is the Zimmer-Biomet closed merger finally around the corner? 5 things to know
Centinel Spine reaches 20k milestone with STALIF C — 5 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
